Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Record of Telephone Conversation, August 2, 2011, Anascorp


Submission Type: BLA    Submission ID: 125335/0    Office: OBRR
Centruroides (Scorpion) Immune F(ab')2 (Equine) Injection
Rare Disease Therapeutics, Inc. (RDT)
Telecon Date/Time: 02-Aug-2011 12:10 PM        Initiated by FDA? Yes
Telephone Number: (619) 328-5370
Communication Categorie(s):
1. Other - Post Marketing Commitments
Telecon Summary:
PMC follow-up
FDA Participants: Donald Ertel
Non-FDA Participants: RDT: Jennifer Spinella
Trans-BLA Group: No
Related STNs: None
Related PMCs: None
Telecon Body:

RDT submitted the draft of the PMCs and written commitments discussed in the teleconference on 08/02/11@ 11:30am. 
Discussion: We found the content, and expected completion of Dec 31, 2011 to be acceptable. 
I stated that we expect to see --------------------(b)(4)-----------------------------.
RDT stated that they will submit an amendment to the submission for the PMCs and written commitments today, 08/02/11. 
Call ended 12:20 PM

Page Last Updated: 09/25/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English